Block copolymer-coated endoprosthesis

Patent metadata

Field	Value
Publication number	US-9314551-B2
Application number	US-201113105473-A
Country	US
Kind code	B2
Filing date	May 11, 2011
Priority date	May 14, 2010
Publication date	Apr 19, 2016
Grant date	Apr 19, 2016

Abstract

In embodiments, a stent includes a copolymer having a modulus of about 10 MPa or less and exhibiting hydrolytic degradation substantially by surface erosion. For example, the copolymer can include elastic segments formed of trimethyl carbonate polymer or copolymer, and rigid segments formed of a lactide, glycolide, ε-caprolactone polymer or copolymer.

First claim

What is claimed is:

1. A stent, comprising:
a biodegradable metal stent body comprising Mg, Fe, or an alloy thereof;
a copolymer coating disposed directly on the biodegradable metal stent body, the copolymer coating comprising elastic segments and rigid segments, the elastic segments being formed of a trimethyl carbonate polymer or copolymer that degrades by bulk hydrolysis, the rigid segments comprising a lactide, glycolide, ε-caprolactone polymer or copolymer that degrades by enzymatic surface erosion, the copolymer coating being cross-linked, the copolymer coating having an elastic modulus of 10 MPa or less and exhibiting degradation by surface erosion over a period of 20 days or more; and
one or more inorganic materials mixed into the copolymer coating;
wherein the copolymer coating is functionalized with maleic anhydride.

2. The stent of claim 1 wherein the copolymer coating further comprises a therapeutic agent.

3. The stent of claim 1 wherein the biodegradable metal stent body further comprises cobalt and chromium.

4. The stent of claim 1 wherein the copolymer coating is on an abluminal surface of the stent body.

5. The stent of claim 1 wherein the rigid segments have an elastic modulus of 200 MPa or more based on a measurement of a homopolymer of rigid segments.

6. The stent of claim 5 wherein the rigid segments exhibit hydrolytic degradation by bulk erosion.

7. The stent of claim 2 wherein the therapeutic agent is paclitaxel.

8. A stent, comprising:
a biodegradable metal stent body comprising Mg, Fe, or an alloy thereof;
a copolymer coating disposed directly on the biodegradable metal stent body, the copolymer coating comprising elastic segments and rigid segments;
wherein the elastic segments are formed of a trimethyl carbonate polymer or copolymer that degrades by bulk hydrolysis;
wherein the rigid segments comprise a lactide, glycolide, ε-caprolactone polymer or copolymer that degrades by enzymatic surface erosion;
wherein the copolymer coating is cross-linked by irradiation;
wherein the copolymer coating has an elastic modulus of 20 MPa or less and exhibits degradation over a period of 20 days or more; and
a therapeutic agent incorporated into the copolymer coating;
wherein the elastic segments are functionalized with maleic anhydride for abluminal surface adhesion.

9. The stent of claim 8 , wherein the therapeutic agent includes paclitaxel.

10. A stent, comprising:
a biodegradable metal stent body comprising iron;
a copolymer coating disposed directly on the biodegradable metal stent body, the copolymer coating comprising elastic segments and rigid segments;
wherein the elastic segments are formed of a trimethyl carbonate polymer or copolymer that degrades by bulk hydrolysis;
wherein the rigid segments comprise a lactide, glycolide, ε-caprolactone polymer or copolymer that degrades by enzymatic surface erosion;
wherein the copolymer coating is cross-linked by irradiation;
wherein the copolymer coating has an elastic modulus of 20 MPa or less and exhibits degradation over a period of 20 days or more; and
a therapeutic agent incorporated into the copolymer coating;
wherein the elastic segments are functionalized with maleic anhydride for abluminal surface adhesion.

11. The stent of claim 10 , wherein the therapeutic agent includes paclitaxel.

Assignees

• Atanasoska Liliana
• Rahi Mourad
• Warner Robert W
• Boston Scient Scimed Inc

Inventors

• Atanasoska Liliana
• Rahi Mourad
• Warner Robert W

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61L31/10

  Macromolecular materials · CPC title

• A61L31/148 Primary

  Materials at least partially resorbable by the body · CPC title

• A61L31/06

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)} · CPC title

• A61L31/16

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title